Compare AT&T Inc. (T) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AT&T Inc. vs Vertex Pharmaceuticals Incorporated — how do they compare? AT&T Inc. trades at $22.29 (market cap $152.52B), while Vertex Pharmaceuticals Incorporated trades at $481.47 (market cap $121.95B). The key difference: AT&T Inc. is the larger of the two by market cap, and AT&T Inc. pays a 5.06% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.
| T | VRTX | |
|---|---|---|
Market Cap | $152.52B | $121.95B |
Sector | Media | Health |
52-Week High | $29.62 | $529.59 |
52-Week Low | $20.49 | $366.54 |
Enterprise Value | $297.87B | $116.69B |
Dividend Yield | 5.06% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AT&T Inc.
AT&T Inc. is a communications holding company. The Company, through its subsidiaries and affiliates, provides local and long-distance phone service, wireless and data communications, Internet access and messaging, IP-based and satellite television, security services, telecommunications equipment, and directory advertising and publishing.
Read more on T →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
